Who can administer
Registered competent doctor or nurse in specialist unit only
Important information
- Severe, life-threatening reactions have been reported. See Monitoring section
- Medicines to avoid prior to regadenoson use
| Medicine |
Notes |
| Methylxanthines including caffeine and theophylline |
Avoid for at least 12 hours before regadenoson use |
| Dipyridamole |
When possible hold for at least 2 days before regadenoson use |
| In addition to medicines, food and drinks containing methylxanthines would need to be avoided for at least 12 hours prior to use of regadenoson (e.g. coffee, tea, Red bull, chocolate, cola beverages) |
Available preparations
Rapiscan 400 microgram in 5ml solution for injection (80 micrograms/ml)
Reconstitution
Already in solution
Infusion fluids
Not required. However injection of Regadenoson should be followed by saline, and then the radiopharmaceutical (see method)
Methods of intravenous administration
Slow intravenous injection (into peripheral vein)
1. Administer as a rapid, 10-second injection into a peripheral vein using a 22-gauge or larger catheter or needle
2. Follow immediately with 5 ml of sodium chloride 0.9% solution for injection, then
3. Follow after 10 to 20 seconds with the radiopharmaceutical . The radiopharmaceutical may be injected directly into the same catheter as regadenoson
Dose in adults
For use in Myocardial Perfusion Imaging(MPI)
- Administer a single injection of 400 micrograms regadenoson (5 ml) into a peripheral vein
- No dose adjustment necessary for body weight
- May be used ONCE only within a 24 hour period
Monitoring
- Cardiorespiratory resuscitation equipment must be available for immediate use
- Continuous ECG monitoring should be performed
- Monitor vital signs at frequent intervals until ECG parameters, heart rate and blood pressure have returned to pre-dose levels
- Monitor patients for signs of myocardial ischaemia, hypotension, clinically significant increases in blood pressure (which can lead to hypertensive crisis), TIA/CVA, seizure activity, atrial fibrillation or flutter, bronchoconstriction, Long QT syndrome, sinoatrial and atrioventricular nodal block
Further information
- Aminophylline may be administered in doses ranging from 50 to 250mg by slow intravenous injection to attenuate severe and/or persistant adverse reactions to regadenoson, but should not be used solely for the purpose of terminating a seizure induced by regadenoson
Storage
Store below 250C
References
SPC Downloaded from EMEA 6th Jan 2021
Therapeutic classification
Selective coronary vasodilator
